NASDAQ:OABI OmniAb (OABI) Stock Forecast, Price & News $5.19 -0.09 (-1.70%) (As of 09/29/2023 08:53 PM ET) Add Compare Share Share Today's Range$5.11▼$5.3450-Day Range$4.98▼$5.9352-Week Range$1.91▼$10.50Volume925,100 shsAverage Volume599,446 shsMarket Capitalization$602.91 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OmniAb MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside92.7% Upside$10.00 Price TargetShort InterestBearish4.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 6 Articles This WeekInsider TradingAcquiring Shares$246,600 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.45) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector533rd out of 970 stocksCommercial Physical Research Industry9th out of 14 stocks 3.5 Analyst's Opinion Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, OmniAb has a forecasted upside of 92.7% from its current price of $5.19.Amount of Analyst CoverageOmniAb has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.90% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in OmniAb has recently increased by 9.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OABI. Previous Next 2.5 News and Social Media Coverage News SentimentOmniAb has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for OmniAb this week, compared to 1 article on an average week.MarketBeat Follows3 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have bought more of their company's stock than they have sold. Specifically, they have bought $246,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of OmniAb is held by insiders.Percentage Held by Institutions58.73% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OmniAb are expected to grow in the coming year, from ($0.45) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OmniAb is -22.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OmniAb is -22.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OmniAb (NASDAQ:OABI) StockOmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.Read More OABI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OABI Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comHead to Head Contrast: OmniAb (NASDAQ:OABI) versus FOXO Technologies (NYSE:FOXO)September 30, 2023 | americanbankingnews.comOmniAb, Inc. (NASDAQ:OABI) Receives Consensus Rating of "Buy" from AnalystsOctober 2, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 26, 2023 | msn.comImmunovant drives OmniAb higher after data update; argenx slipsSeptember 25, 2023 | msn.comOmniAb: Hold For GrowthSeptember 17, 2023 | seekingalpha.comOABIW OmniAb, Inc. WT EXP 110127September 5, 2023 | finance.yahoo.comOmniAb to Participate in Two Investor Conferences in SeptemberAugust 18, 2023 | finance.yahoo.comOmniAb President Acquires 2.0% More StockOctober 2, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 16, 2023 | finance.yahoo.comNeed To Know: Analysts Just Made A Substantial Cut To Their OmniAb, Inc. (NASDAQ:OABI) EstimatesAugust 15, 2023 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call TranscriptAugust 13, 2023 | markets.businessinsider.comTruist Financial Remains a Buy on OmniAb (OABI)August 13, 2023 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To KnowAugust 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Evolv Technologies Holdings (EVLV), Viavi Solutions (VIAV) and OmniAb (OABI)August 11, 2023 | msn.comHC Wainwright & Co. Reiterates OmniAb (OABI) Buy RecommendationAugust 11, 2023 | finance.yahoo.comOmniAb Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 8, 2023 | finance.yahoo.comOmniAb Announces the Passing of Director Sunil PatelJuly 31, 2023 | finance.yahoo.comOmniAb to Report Second Quarter 2023 Financial Results on August 10July 17, 2023 | finance.yahoo.comWith 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big gunsJune 29, 2023 | seekingalpha.comOmniAb: Plenty Of PotentialJune 5, 2023 | finance.yahoo.comPresident of OmniAb Matthew Foehr Buys 22% More SharesMay 26, 2023 | seekingalpha.comOmniAb (OABI) Investor Presentation - SlideshowMay 17, 2023 | finance.yahoo.comOmniAb Launches OmniDeep™ at the PEGS Boston Conference and ExpoMay 16, 2023 | finance.yahoo.comPresident of OmniAb Matthew Foehr Buys 22% More Shares \May 15, 2023 | seekingalpha.comOmniAb: 6 Months In And Going StrongMay 15, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on OmniAb (OABI)May 14, 2023 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts SubstantiallySee More Headlines Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address OABI Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OABI CUSIPN/A CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployees95Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+92.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,330,000.00 Net MarginsN/A Pretax Margin-51.62% Return on Equity-6.38% Return on Assets-4.33% Debt Debt-to-Equity RatioN/A Current Ratio4.78 Quick Ratio4.78 Sales & Book Value Annual Sales$66.12 million Price / Sales9.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.96 per share Price / Book1.75Miscellaneous Outstanding Shares116,168,000Free Float108,036,000Market Cap$602.91 million OptionableNot Optionable Beta-0.55 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Matthew W. Foehr (Age 50)Pres, CEO & Director Comp: $967.72kMr. Kurt A. Gustafson (Age 55)Exec. VP of Fin. & CFO Comp: $558.48kMr. Charles S. Berkman J.D. (Age 54)Chief Legal Officer & Sec. Comp: $734.33kMs. Cia McCaffreyVP of People & TalentDr. Bill Harriman Ph.D.Sr. VP of Antibody DiscoveryMs. Marie-Cecile van de Lavoir D.V.M.Ph.D., Sr. VP of Technical Operations & GeneticsDr. Christel Iffland Ph.D.Sr. VP of Antibody TechnologiesDr. Douglas S. Krafte Ph.D. (Age 65)Sr. VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head Ms. Donna Ventura CPASr. VP of Corp. ControllerMore ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXZymeworksNYSE:ZYMECibusNASDAQ:CBUSAura BiosciencesNASDAQ:AURAKalVista PharmaceuticalsNASDAQ:KALVView All CompetitorsInsiders & InstitutionsBarclays PLCBought 34,195 shares on 9/21/2023Ownership: 0.029%Cornerstone Capital Inc.Sold 8,643 shares on 8/21/2023Ownership: 0.143%California State Teachers Retirement SystemBought 2,968 shares on 8/21/2023Ownership: 0.092%Nuveen Asset Management LLCBought 23,235 shares on 8/16/2023Ownership: 0.247%Royal Bank of CanadaBought 5,811 shares on 8/15/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions OABI Stock - Frequently Asked Questions Should I buy or sell OmniAb stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OABI shares. View OABI analyst ratings or view top-rated stocks. What is OmniAb's stock price forecast for 2023? 9 Wall Street analysts have issued twelve-month target prices for OmniAb's shares. Their OABI share price forecasts range from $6.00 to $13.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 92.7% from the stock's current price. View analysts price targets for OABI or view top-rated stocks among Wall Street analysts. How have OABI shares performed in 2023? OmniAb's stock was trading at $3.60 at the beginning of the year. Since then, OABI stock has increased by 44.2% and is now trading at $5.19. View the best growth stocks for 2023 here. When is OmniAb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023. View our OABI earnings forecast. How were OmniAb's earnings last quarter? OmniAb, Inc. (NASDAQ:OABI) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.04. The business earned $6.95 million during the quarter, compared to analyst estimates of $13.05 million. What is OmniAb's stock symbol? OmniAb trades on the NASDAQ under the ticker symbol "OABI." How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OmniAb's stock price today? One share of OABI stock can currently be purchased for approximately $5.19. How much money does OmniAb make? OmniAb (NASDAQ:OABI) has a market capitalization of $602.91 million and generates $66.12 million in revenue each year. The company earns $-22,330,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. How can I contact OmniAb? OmniAb's mailing address is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.omniab.com. The company can be reached via phone at 510-250-7800 or via email at investors@omniab.com. This page (NASDAQ:OABI) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.